Secondary Bacterial Infections in Post-COVID-19 Mucormycosis Cases: a Retrospective Study at Imam Khomeini Hospital Complex, March 2020-April 2021

Overview

Journal Iran J Microbiol

Publisher Tehran University of Medical Sciences

Specialty Infectious Diseases

Date 2024 Jul 15

PMID 39005610

Authors

Mohsen Meidani

Sepideh Zahak Miandoab

Amir Salami

Sajedeh Jadidi

Marjan Sohrabi

Parvaneh Ebrahimi Alavijeh

Sara Ghaderkhani

Hamid Emadi Koochak

Arezoo Salami Khaneshan

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: To explore the prevalence and characteristics of secondary bacterial infections among patients suffering from mucormycosis following COVID-19 infection.

Materials And Methods: We conducted a cross-sectional, retrospective analysis from March 2020 to April 2022 at Imam Khomeini Hospital Complex in Tehran. The study included patients with histopathologically confirmed mucormycosis and documented secondary bacterial infections. We extracted and analyzed data from hospital records using SPSS software, version 26.

Results: The study comprised 27 patients, with a predominance of females (70.4%) and an average age of 56 years. The majority of these patients (63%) had pre-existing diabetes mellitus. The severity of their COVID-19 infections varied. Treatment regimens included immunosuppressive drugs and antibiotics. Rhinocerebral mucormycosis was the most common form observed. The predominant secondary infections involved the urinary tract, respiratory system, bloodstream (bacteremia), and soft tissues, with resistant strains of and being the most frequently identified microorganisms. Notably, cases of bacteremia and pneumonia exhibited a higher mortality rate. Ultimately, 55.6% of patients were discharged, while 44.4% succumbed to their infections.

Conclusion: Patients recovering from COVID-19 with mucormycosis are significantly susceptible to secondary bacterial infections, particularly those with diabetes mellitus or those undergoing immunosuppressive therapy. Such infections compound the morbidity and mortality risks in this vulnerable patient cohort.

References

Meawed T, Ahmed S, Mowafy S, Samir G, Anis R . Bacterial and fungal ventilator associated pneumonia in critically ill COVID-19 patients during the second wave. J Infect Public Health. 2021; 14(10):1375-1380. PMC: 8349397. DOI: 10.1016/j.jiph.2021.08.003. View

Garg D, Muthu V, Sehgal I, Ramachandran R, Kaur H, Bhalla A . Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): Case Report and Systematic Review of Literature. Mycopathologia. 2021; 186(2):289-298. PMC: 7862973. DOI: 10.1007/s11046-021-00528-2. View

Sharma A, Goel A . Mucormycosis: risk factors, diagnosis, treatments, and challenges during COVID-19 pandemic. Folia Microbiol (Praha). 2022; 67(3):363-387. PMC: 8881997. DOI: 10.1007/s12223-021-00934-5. View

Bhattacharyya A, Sarma P, Sharma D, Das K, Kaur H, Prajapat M . Rhino-orbital-cerebral-mucormycosis in COVID-19: A systematic review. Indian J Pharmacol. 2021; 53(4):317-327. PMC: 8411962. DOI: 10.4103/ijp.ijp_419_21. View

Falcone M, Tiseo G, Giordano C, Leonildi A, Menichini M, Vecchione A . Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: a prospective observational study. J Antimicrob Chemother. 2020; 76(4):1078-1084. PMC: 7799007. DOI: 10.1093/jac/dkaa530. View

Lansbury L, Lim B, Baskaran V, Lim W . Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. 2020; 81(2):266-275. PMC: 7255350. DOI: 10.1016/j.jinf.2020.05.046. View

Veisi A, Bagheri A, Eshaghi M, Rikhtehgar M, Kanavi M, Farjad R . Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: A case report. Eur J Ophthalmol. 2021; 32(4):NP11-NP16. PMC: 9294610. DOI: 10.1177/11206721211009450. View

Cao J, Tu W, Cheng W, Yu L, Liu Y, Hu X . Clinical Features and Short-term Outcomes of 102 Patients with Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis. 2020; 71(15):748-755. PMC: 7184479. DOI: 10.1093/cid/ciaa243. View

Blaize M, Mayaux J, Nabet C, Lampros A, Marcelin A, Thellier M . Fatal Invasive Aspergillosis and Coronavirus Disease in an Immunocompetent Patient. Emerg Infect Dis. 2020; 26(7):1636-1637. PMC: 7323532. DOI: 10.3201/eid2607.201603. View

10.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497-506. PMC: 7159299. DOI: 10.1016/S0140-6736(20)30183-5. View

11.

Selarka L, Sharma S, Saini D, Sharma S, Batra A, Waghmare V . Mucormycosis and COVID-19: An epidemic within a pandemic in India. Mycoses. 2021; 64(10):1253-1260. PMC: 8446956. DOI: 10.1111/myc.13353. View

12.

Sharifipour E, Shams S, Esmkhani M, Khodadadi J, Fotouhi-Ardakani R, Koohpaei A . Evaluation of bacterial co-infections of the respiratory tract in COVID-19 patients admitted to ICU. BMC Infect Dis. 2020; 20(1):646. PMC: 7461753. DOI: 10.1186/s12879-020-05374-z. View

13.

Prakash H, Ghosh A, Rudramurthy S, Singh P, Xess I, Savio J . A prospective multicenter study on mucormycosis in India: Epidemiology, diagnosis, and treatment. Med Mycol. 2018; 57(4):395-402. DOI: 10.1093/mmy/myy060. View

14.

Rahman F, Islam M, Bhuiyan M . Mucormycosis or black fungus infection is a new scare in South Asian countries during the COVID-19 pandemic: Associated risk factors and preventive measures. J Med Virol. 2021; 93(12):6447-6448. PMC: 8426961. DOI: 10.1002/jmv.27207. View

15.

Mehta S, Pandey A . Rhino-Orbital Mucormycosis Associated With COVID-19. Cureus. 2020; 12(9):e10726. PMC: 7599039. DOI: 10.7759/cureus.10726. View

16.

Singh A, Singh R, Joshi S, Misra A . Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab Syndr. 2021; 15(4):102146. PMC: 8137376. DOI: 10.1016/j.dsx.2021.05.019. View

17.

Daria S, Asaduzzaman M, Shahriar M, Islam M . The massive attack of COVID-19 in India is a big concern for Bangladesh: The key focus should be given on the interconnection between the countries. Int J Health Plann Manage. 2021; 36(5):1947-1949. PMC: 8239703. DOI: 10.1002/hpm.3245. View